3,179 Shares in argenx SE (NASDAQ:ARGX) Bought by Capula Management Ltd

Capula Management Ltd acquired a new stake in argenx SE (NASDAQ:ARGX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 3,179 shares of the company's stock, valued at approximately $1,955,000.

A number of other institutional investors have also made changes to their positions in ARGX. Whipplewood Advisors LLC acquired a new stake in argenx during the 4th quarter valued at $37,000. Global Retirement Partners LLC lifted its stake in shares of argenx by 369.2% during the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock worth $38,000 after buying an additional 48 shares during the last quarter. FIL Ltd acquired a new stake in shares of argenx during the 4th quarter worth about $38,000. Jones Financial Companies Lllp boosted its holdings in shares of argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock worth $41,000 after buying an additional 61 shares during the period. Finally, Huntington National Bank grew its stake in argenx by 1,133.3% in the 4th quarter. Huntington National Bank now owns 74 shares of the company's stock valued at $46,000 after buying an additional 68 shares during the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

argenx Price Performance

ARGX stock traded up $34.72 during midday trading on Friday, reaching $580.94. 536,659 shares of the stock were exchanged, compared to its average volume of 306,638. The stock has a market capitalization of $35.30 billion, a PE ratio of -660.16 and a beta of 0.60. argenx SE has a 52 week low of $352.77 and a 52 week high of $678.21. The company has a fifty day moving average price of $607.87 and a 200 day moving average price of $604.46.

Remove Ads

argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.60. The company had revenue of $761.22 million for the quarter, compared to analysts' expectations of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. As a group, analysts anticipate that argenx SE will post 3.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ARGX has been the topic of a number of research reports. Wedbush reaffirmed an "outperform" rating and issued a $715.00 price objective on shares of argenx in a report on Friday. Deutsche Bank Aktiengesellschaft raised shares of argenx from a "sell" rating to a "hold" rating in a research report on Wednesday, March 12th. Citigroup reaffirmed an "outperform" rating on shares of argenx in a research report on Friday, February 28th. JMP Securities boosted their price objective on shares of argenx from $606.00 to $696.00 and gave the company a "market outperform" rating in a report on Tuesday, January 14th. Finally, William Blair reaffirmed an "outperform" rating on shares of argenx in a report on Friday, February 28th. Three analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $690.33.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.